Article
Recent advances in targeting leucine-rich repeat kinase 2 as a potential strategy for the treatment of Parkinson's disease.
Bioorganic chemistry - 1 Dec 2023
Cao Ruiwei, Chen Caiping, Wen Jing, Zhao Weihe, Zhang Chaojun, Sun Longhui, Yuan Liyan, Wu Chunlei, Shan Lei, Xi Meiyang, Sun Haopeng
Abstract excerpt
Parkinson's disease (PD) is the second most common neurodegenerative disease. Several single gene mutations involved in PD have been identified such as leucine-rich repeat kinase 2 (LRRK2), the most common cause of sporadic and familial PD. Its mutations have attracted much attention to therapeutically targeting this kinase. To date, many compounds including small chemical molecules with diverse scaffolds and RNA...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.